Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study

Mostrar otras versiones (1)

COVID19 in patients affected by lymphoma represents an important challenge because of the higher mortality rate. Anti‐SARS‐CoV‐2 monoclonal antibodies (anti‐S MoAbs) appear promising in this setting. We report a monocentric retrospective study including 176 patients affected by lymphoma which develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Assanto, Giovanni Manfredi, Di Rocco, Alice, Malfona, Francesco, Capriata, Marcello, Del Giudice, Ilaria, Petrucci, Luigi, Girardi, Paola, D’Elia, Gianna Maria, Martelli, Maurizio, Gentile, Giuseppe, Micozzi, Alessandra, Pulsoni, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877821/
https://www.ncbi.nlm.nih.gov/pubmed/36521843
http://dx.doi.org/10.1002/hon.3113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877821/
https://www.ncbi.nlm.nih.gov/pubmed/36521843
http://dx.doi.org/10.1002/hon.3113

Ejemplares similares